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Aim To compare the prognostic performance of three ma-
jor risk scoring systems including global registry for acute 
coronary events (GRACE), thrombolysis in myocardial in-
farction (TIMI), and prediction of 30-day major adverse car-
diovascular events after primary percutaneous coronary 
intervention (RISK-PCI).
Methods This single-center retrospective study involved 
200 patients with acute coronary syndrome (ACS) who 
underwent invasive diagnostic approach, ie, coronary 
angiography and myocardial revascularization if appro-
priate, in the period from January 2014 to July 2014. The 
GRACE, TIMI, and RISK-PCI risk scores were compared for 
their predictive ability. The primary endpoint was a com-
posite 30-day major adverse cardiovascular event (MACE), 
which included death, urgent target-vessel revasculariza-
tion (TVR), stroke, and non-fatal recurrent myocardial in-
farction (REMI).
Results The c-statistics of the tested scores for 30-day 
MACE or area under the receiver operating characteristic 
curve (AUC) with confidence intervals (CI) were as follows: 
RISK-PCI (AUC = 0.94; 95% CI 1.790-4.353), the GRACE score 
on admission (AUC = 0.73; 95% CI 1.013-1.045), the GRACE 
score on discharge (AUC = 0.65; 95% CI 0.999-1.033). The 
RISK-PCI score was the only score that could predict TVR 
(AUC = 0.91; 95% CI 1.392-2.882). The RISK-PCI scoring sys-
tem showed an excellent discriminative potential for 30-
day death (AUC = 0.96; 95% CI 1.339-3.548) in comparison 
with the GRACE scores on admission (AUC = 0.88; 95% CI 
1.018-1.072) and on discharge (AUC = 0.78; 95% CI 1.000-
1.058).
Conclusions In comparison with the GRACE and TIMI 
scores, RISK-PCI score showed a non-inferior ability to pre-
dict 30-day MACE and death in ACS patients. Moreover, 
RISK-PCI was the only scoring system that could predict re-
current ischemia requiring TVR.
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Variations in clinical appearance and outcome in patients 
with acute coronary syndrome (ACS) require a reliable 
method of risk assessment for further major adverse cardi-
ac events (MACE) during the ACS treatment. Risk stratifica-
tion is a useful tool for planning early treatment, discharge, 
and rehabilitation of ASC patients, performing research af-
ter ACS, and expediting the definitive decision about fur-
ther treatment (1,2).
Different scores are in use for the estimation of ACS out-
come. Thrombolysis in myocardial infarction (TIMI) is a sim-
ple bedside score that predicts 30-day mortality in patients 
with ST-elevation myocardial infarction (STEMI). Also, the 
TIMI score evaluates 14-day adverse events in patients with 
unstable angina (UA)/non-ST-segment elevation myocar-
dial infarction (NSTEMI). Several studies confirmed the ef-
ficacy of this index in the prognosis of mortality within 
30-day period, although some attenuation was shown for 
patients older than 65 years (3-6). However, the TIMI score 
was based on clinical studies including selected popula-
tions of patients with low comorbidity rates and it does not 
always reflect the reality in clinical practice.
Global registry for acute coronary events (GRACE) score 
demonstrated its superiority in the assessment of 6-months 
mortality risk (7,8). Unlike TIMI, the GRACE score was derived 
from the Global Registry of Acute Coronary Syndrome data. 
As it was based on a wider sample of unselected population 
(9), it is more reliable for the routine clinical use. Several in-
ternational reports compared the GRACE score with the TIMI 
score, showing that the GRACE score was a better predictor 
of clinical outcome than the TIMI score (10,11).
Predicting 30-day major adverse cardiovascular events af-
ter primary percutaneous coronary intervention (RISK-PCI 
score) was developed to predict 30-day MACE, such as 
non-fatal REMI, death, and cerebrovascular insult, in pa-
tients with STEMI after percutaneous coronary interven-
tion (PCI) (12). The definitive value of all the scores is influ-
enced by various clinical factors, such as score variables, 
period of the score evaluation, patient population, and 
analyzed adverse cardiovascular outcomes. RISK-PCI score 
has not been tested in patients with UA/NSTEMI. Although 
the GRACE score has already been established as the score 
of choice for the risk estimation (13), RISK-PCI also seems 
to be reliable considering that it includes clinical, labora-
tory, and diagnostic parameters. Our hypothesis was that 
the RISK-PCI score was as accurate as the GRACE and TIMI 
scores in predicting a composite MACE in patients with 
UA/NSTEMI.
The aim of our study was to estimate the prognostic po-
tential of the RISK-PCI score and compare it with GRACE 
and TIMI scores for prediction of composite MACE occur-
rence within 30 days of a patient’s presentation with ACS.
METHODS
Patients
This single-center retrospective study included 200 pa-
tients with signs and symptoms compatible with ACS who 
were admitted to hospital between January 2014 and July 
2014. There were 140 men and 60 women, with the mean 
age (±standard deviation, SD) of 62.3 ± 10.8 years (Table 1). 
The signs and symptoms compatible with ACS were acute 
chest pain or equivalent, and/or increase of cardiac tro-
ponin over the upper reference limit, and/or new signifi-
cant ST- segment–T wave (ST–T) changes or new left bun-
dle branch block [LBBB] in electrocardiogram (ECG), and/
or images showing loss of viable myocardium or regional 
contractile abnormality (14). Clinical data, including previ-
ous medical history and risk factors, were taken into con-
sideration.
Exclusion criteria were refusal to give consent for inva-
sive treatment, active or recent internal bleeding, history 
of bleeding after non-steroid anti-inflammatory agents, 
known bleeding diathesis, intracerebral mass or aneurysm, 
intolerance or allergy to acetylsalicylates or clopidogrel, 
history of hypersensitivity to iodinated contrast media, car-
diogenic shock at admission, non-cardiac conditions that 
could interfere with compliance with the protocol or ne-
cessitate interruption of the treatment with thienopyri-
dines, and coexisting conditions associated with a limited 
life expectancy at 30-day follow-up. Revascularization pro-
cedure was performed in all patients in accordance with 
the applicable clinical practice guidelines for PCI (15). Be-
fore PCI, patients had been administered anticoagulant 
therapy and a loading dose of acetylsalicylates and clopi-
dogrel. All patients were informed in detail about the inter-
vention procedure and all signed a written consent.
Primary PCI was performed via femoral approach, using 
standard 6F or 7F guiding catheters. The procedure be-
gan with a visualization of the non-infarction related artery 
(IRA), followed by the visualization of the IRA. Stenting was 
performed in patients with anatomically-suitable artery 
with a diameter of ≥2.0 mm and without excessive tor-
tuosity and extremely angulated lesions. Angioplasty 
without stenting was performed on selected pa-
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tients who were candidates for urgent surgery or patients 
with small and tortuous or highly calcified IRA. Drug-elut-
ing stents (DES) were suggested for selected patients with 
in-stent restenosis, diabetes mellitus, very long lesions, or 
bifurcated lesions. The decision about DES implantation 
was left to the discretion of the surgeon. In our trial, man-
ual aspiration was used sporadically and was not included 
in the final analysis. Flow grades were assessed according 
to the TIMI criteria. Temporary pacemaker was placed in all 
patients with high-grade atrioventricular (AV) block or bra-
diarrhythmia and hemodynamic compromise.
After PCI, dual antiplatelet therapy was prescribed for 12 
months to all patients included in the study.
TABlE 1. Baseline demographic, clinical, angiographic, and procedural characteristics of the patients with acute coronary syndrome*




NSTEMI (n = 69) and  
UA (n = 15)
STEMI 
(n = 116)
Age (years, mean±SD)  62.3 ± 10.8  63.3 ± 10.4  61.4 ± 11.1
Sex (men/women) 140/60  55/29  85/31
Medical history
prior MI  40 (20.0)  25 (29.8)  15 (12.9)
prior AP 151 (75.5)  76 (90.5)  75 (64.6)
prior CHF  39 (19.5)  26 (31.0)  13 (11.2)
anterior MI  57 (28.5)  23 (27.4)  34 (29.3)
dyslipidemia 174 (87.0)  74 (88.1) 100 (86.2)
>3 standard risk factors 140 (70.0)  66 (78.6)  74 (63.8)
hypertension 130 (65.0)  63 (75.0)  67 (57.8)
diabetes mellitus  26 (13.0)  10 (11.9)  16 (13.8)
current smokers 112 (56.0)  41 (48.8)  70 (60.3)
Clinical characteristics
KILLIP† class I 156 (78.0)  62 (73.8)  94 (81.0)
KILLIP† class II  41 (20.5)  20 (23.8)  21 (18.1)
KILLIP† class III   3 (1.5)   2 (2.4)   1 (0.9)
asystoly   5 (2.5)   0 (0.0)   5 (4.3)
ST elevation 116 (58.0)   0 (0.0) 116 (100.0)
ST depression 117 (58.5)  55 (65.5)  62 (53.4)
AVB III   4 (2.0)   0 (0.0)   4 (3.4)
ABBB  10 (5.0)   3 (3.6)   7 (6.0)
heart rate (beats/min; median with interquartile range)  80.0 (40.0-300.0)  80.0 (47.0-120.0)  78.5 (40.0-300.0)
SBP (mmHg, median with interquartile range) 140.0 (50.0-220.0) 150.0 (90.0-220.0) 135.0 (50.0-220.0)
LVEF (%, median with interquartile range)  45.0 (5.0-66.0)  45.0 (15.0-65.0)  45.0 (5.0-66.0)
laboratory data on admission
leukocyte count (x 10−9/L; median with interquartile range)   9.9 (4.4-28.9)   9.5 (4.4-22.5)  10.4 (4.7-28.9)
glucose (mmol/L, median with interquartile range)   7.7 (3.6-53.6)   7.2 (4.1-23.0)   8.2 (3.6-53.6)
creatinine (mmol/L, median with interquartile range) 104.0 (56.4-148.8) 104.5 (70.1-152.0) 103.9 (56.4-1488.0)
creatinine clearance (mL/min, median with interquartile range)  69.9 (29.8-171.9)  66.0 (29.8-138.3)  71.8 (30.9-171.9)
peak troponin I (µg/L; median with interquartile range)   0.8 (0.0-50.0)   0.5 (0.0-11.2)   1.6 (0.0-50.0)
Angiographic findings
diameter of IRA≤2,5 mm (median with interquartile range)  24 (12.0)  11 (13.1)  13 (11.2)
pre-procedural TIMI flow 0  78 (39.0)  13 (15.5)  65 (56.0)
final TIMI flow grade <3  63 (31.5)  32 (38.1)  31 (26.7)
temporary pacemaker   4 (2.0)   0 (0.0)   4 (3.4)
*Abbreviations: ACS – acute coronary syndrome; NSTEMI – non ST elevation myocardial infartion; UA – unstable angina; STEMI – ST elevation myo-
cardial infarction; SD – standard deviation; MI – myocardial infarction; AP – angina pectoris; CHF – congestive heart failure; AVB III – atrioventricular 
block grade III; ABBB – acute bundle branch block; SBP – systolic blood pressure; lVEF – left ventricular ejection fraction; IRA – infarction-related 
artery; CABG – coronary artery bypass grafting.
†KIllIP – classification of the severity of heart failure by Thomas Killip: class I – no heart failure; class II - heart failure, diagnostic criteria include rales, 
S3 gallop, and venous hypertension; class III - pulmonary edema; class IV – cardiogenic shock.
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Method
The primary endpoint was a composite 30-day MACE 
consisting of death, target-vessel revascularization (TVR), 
stroke, and non-fatal recurrent myocardial infarction 
(REMI). TVR was defined as ischemia-driven revascular-
ization of the IRA during a follow-up period (16). Stroke 
was defined as a new onset of focal or global neurologi-
cal deficit lasting more than 24 hours. The presence of re-
current ischemic symptoms for 20 minutes or longer, re-
occurrence of ST-segment deflection, T wave inversion or 
new pathognomonic Q waves in at least two contiguous 
leads, and increase in cardiac troponin above the upper 
reference limit and over 20% of the lowest recovery level 
from the index myocardial infarction (MI) were considered 
as REMI (14).
A planned staged PCI was not considered a TVR. All pa-
tients were followed up for 30 days or until death, which-
ever occurred first. Follow-up data were obtained in sched-
uled telephone interviews and outpatient visits. No patient 
was lost to follow-up.
Four scores computed from the previously acquired data 
included TIMI score, GRACE score on admission, GRACE 
score on discharge, and RISK-PCI score.
The TIMI score for NSTEMI and UA involves patient age, 
risk factors for coronary artery disease (hypertension, 
dyslipidemia, diabetes mellitus, active smoking, and 
heredity for coronary disease), prior coronary stenosis 
of 50% or more, use of acetylsalicylates in the previous 
seven days, at least 2 angina events in the previous 24 
hours, increased serum cardiac biomarkers, and ST-seg-
ment deviation on ECG at presentation. The score of sev-
en points is an important predictor of the development 
of adverse events such as new MI or REMI, death or se-
vere recurrent ischemia requiring urgent revasculariza-
tion (17). The TIMI score for STEMI involves patient age, 
systolic blood pressure value, heart failure, body mass, 
FIGURE 1. Flow diagram of the patients. ACS – acute coronary syndrome; UA – unstable angina; NSTEMI – non ST elevation myo-
cardial infarction; STEMI – ST elevation myocardial infarction; ePCI – elective percutaneous coronary intervention; pPCI – primary 
percutaneous coronary intervention; CAGB – coronary arterial bypass grafting.
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anterior MI or left bundle branch block, presence of dia-
betes mellitus, hypertension or angina pectoris, and the 
period between the symptom onset and the beginning 
of treatment (18).
The GRACE score on admission includes patient age, heart 
rate, systolic blood pressure value, increased laboratory 
cardiac markers and serum creatinine level, and ST devia-
tion or asystole on ECG (7). The GRACE score on discharge 
includes patient age, aforementioned clinical signs and 
laboratory parameters, ST depression on ECG, prior MI, and 
in-hospital coronary intervention (19). The GRACE ACS risk 
calculators are available online (20).
The RISK-PCI score includes 12 variables as follows: patient 
age, prior MI, anterior MI, acute bundle branch block and 
high-grade AV block, laboratory findings (leukocyte counts, 
glycemia, and creatinine clearance), echocardiographic 
evaluation of left ventricular ejection fraction (EF), angio-
graphic assessment of the IRA diameter, and initial and post-
procedural TIMI flow grade. The total score ranges from 0 to 
20. Patients with 5-6.5 score are at high risk (12).
Statistical analysis
Statistical analysis was performed using a commercial-
ly available statistical software program (SPSS 13.0, Inc, 
Chicago Il, US). Normality of data distribution was as-
sessed using Smirnov- Kolmogorov test. In addition to 
the usual parameters of central tendency (mean with 
standard deviation [SD]), Student’s t test was applied to 
test for differences between two related samples. For 
the non-parametric data, analysis was performed using 
the Mann-Whitney test, receiver operating characteristic 
(ROC) curve, and univariate and multivariate logistic re-
gression analysis. The discrimination of the model was 
analyzed by calculating the area under the curve (AUC), 
which represented the accuracy of each value in dis-
criminating high from low risk for patients with adverse 
events. AUC≥0.90 was defined as ‘excellent’, AUC≥0.70 
was ‘good’, and AUC<0.70 was considered ‘inadequate’ 
(21). Calibration was evaluated by the Hosmer-Leme-
show goodness-of-fit test. The probability level in all 
tests was set at 95%.
RESUlTS
Of 200 ACS patients included in the study, STEMI was di-
agnosed in 116 (58.0%), NSTEMI in 69 (34.5%), and UA in 
15 (7.5%) patients (Figure 1).
Incidence of clinical events
The primary composite endpoint MACE occurred in 17 
patients (8.5%) during the 30-day follow-up period in-
cluding death in six cases (3.0%), REMI in two cases (1.0%), 
and urgent myocardial revascularizations due to current 
ischemia in 10 cases (5.2%). One patient had two unde-
sired effects, reinfarction and subsequent fatal outcome. 
No stroke occurred during the follow-up period. Of the 
total of 200 patients, 122 (61.0%) underwent PCI and 13 
(6.5%) underwent coronary artery bypass grafting (CAGB) 
in the same period. Four patients (2%) died in the hospital. 
The cause of death of three patients was the progression 
of heart failure and one patient had a fatal REMI. None of 
the patients used mechanical circulatory assistance while 
hospitalized. Two patients died after discharge from hos-
pital within 20 days.
Risk model calibration and discrimination
The RISK-PCI score expressed an excellent predictive po-
tential for 30-day MACE (AUC = 0.94; 95% CI 1.790-4.353; 
P < 0.001) in comparison with the GRACE scores on admis-
FIGURE 2. Receiver-operating characteristic (ROC) curves 
showing the discriminative ability of the risk scores for the 
prediction of 30-day composite major adverse cardiovascular 
events.
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sion (AUC = 0.73; 95% CI 1.013-1.045; P = 0.002) and dis-
charge (AUC = 0.65; 95% CI 1.000-1.033; P = 0.035; Figure 2). 
The RISK-PCI score was the only score that could point to-
ward TVR (AUC = 0.91; 95% CI 1.392-2.882; P < 0.001; Figure 
3). The RISK-PCI score and GRACE scores on admission and 
discharge showed good discrimination performance for 
death within 30 days of admission. The RISK-PCI score dem-
onstrated an excellent discriminative potential for 30-day 
death (AUC = 0.96; 95% CI 1.339-3.548; P < 0.001) in com-
parison with the GRACE score on admission (AUC = 0.88; 
95% CI 1.018-1.072; P = 0.002) and discharge (AUC = 0.78; 
95% CI 1.000-1.058; P = 0.021; Figure 4).
The TIMI score did not show any statistical significance 
in 30-day prediction of death (AUC = 0.64; 95% CI 0.935-
2.156; P > 0.05), repeated urgent myocardial revasculariza-
tion (AUC = 0.49; 95% CI 0.728-1.382; P > 0.05) or composite 
MACE (AUC = 0.56; 95% CI 0.904-1.490; P > 0.05).
The Hosmer-Lemeshow P values for all subgroups were 
>0.05, suggesting a good model fit (Table 2).
The logistic regression showed that the RISK-PCI score was 
an important predictor of death, urgent revascularization, 
and composite MACE, whereas the GRACE score on ad-
mission was adequate for predicting death and composite 
MACE.
FIGURE 4. Receiver-operating characteristics (ROC) curves 
showing the discriminative ability of the risk scores for the 
prediction of 30-day death.
FIGURE 3. Receiver-operating characteristic (ROC) curves 
showing the discriminative ability of the RISK-PCI algorithm, 
the score predicting 30-day major adverse cardiovascular 
events after primary percutaneous coronary intervention, for 
the prediction of 30-day target-vessel revascularization (TVR).
TABlE 2. Hosmer-lemeshow calibration statistics for RISK-PCI, GRACE, and TIMI risk scores in patients with acute coronary syndrome*
Death TVR MACE
Risk score χ2 P χ2 P χ2 P
RISK-PCI  0.851 0.997 3.509 0.834 2.527 0.922
GRACE on admission  2.156 0.976 4.319 0.827 4.540 0.805
GRACE on discharge 13.796 0.087 5.786 0.671 5.990 0.648
TIMI  6.605 0.252 2.499 0.777 3.046 0.693
*Abbreviations: TVR – target-vessel revascularization; MACE – major adverse cardiac events; RISK-PCI – predicting 30-day major adverse cardiovascu-
lar events after primary percutaneous coronary intervention; GRACE – Global Registry for Acute Coronary Events; TIMI – thrombolysis in myocardial 
infarction.
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The TIMI score was not found to have significant predictive 
potential for 30-day MACE (Table 3).
DISCUSSION
This study was the first to compare different clinical scores, 
GRACE, TIMI, and newly introduced RISK-PCI, for their ability 
to predict possible adverse cardiovascular outcome in 30-
day follow-up period (2,7,12,16). The RISK-PCI score reliably 
predicted a 30-day MACE in ACS patients and was non-in-
ferior to the other two clinical scores. The most important 
advantage of RISK–PCI score was a prediction of TVR.
According to our results, the TIMI score was found to have 
the worst predictive potential, probably due to a relative-
ly small number of parameters used, ie, symptom of the 
acute renal failure, generally accepted as an independent 
predictor of the poor in-hospital survival, was not consid-
ered at all (22,23). Nevertheless, the TIMI score seemed to 
be useful for a quick evaluation of ACS patients during the 
emergency department visit (24). The GRACE risk score 
had the highest prognostic accuracy for long-term mor-
tality at each observed time point. The GRACE risk score 
is unique, because it is based on a large registry of pa-
tients across the entire spectrum of coronary syndromes 
and designed for the prognosis of all-cause mortality at 
six months (19,25). Furthermore, the GRACE score seems 
to be the most suitable for the prediction over a longer 
follow-up period (25). In our study, the RISK-PCI and GRACE 
scores on admission and discharge showed a good dis-
criminative potential regarding the patient stratification 
into low- and high-risk groups. These two scoring systems 
also showed a good prognostic value for the adverse car-
diovascular events in 30-day follow-up period. Specifically, 
every third patient with the RISK-PCI score ≥7 (very high-
risk group) died during the 30-day follow-up, which im-
plies that such patients need close monitoring during 
the acute phase of MI and careful evaluation of the 
dual antiplatelet therapy. Moreover, the high-risk patients 
might also be candidates for complete revascularization 
before discharge from hospital (12). The RISK-PCI score was 
found to be the most precise for the prediction of major 
cardiovascular adverse events, such as death or relevant 
ischemia requiring urgent revascularization. The RISK-PCI 
scoring system had the best predictive value for the MACE 
estimation, with a good discriminative ability, which is not 
surprising considering that RISK-PCI was designed for the 
MACE anticipation from the beginning. On the other hand, 
the GRACE scoring system was not initially intended for 
the MACE estimation, but it has been gradually used for 
the prediction of other adverse incidents during in-hospi-
tal stay, such as re-infarction, arrhythmias, acute conges-
tive heart failure, shock, and cerebrovascular incidents 
(26,27). Prognostic information based exclusively on the 
ECG changes and cardiac markers is insufficient, because 
ECG changes have high specificity but low sensitivity for 
the myocardial ischemia. Furthermore, prognostic poten-
tial of the cardiac markers is attenuated due to the period 
of latency between the moment of cardiac myocyte ne-
crosis and subsequent entrance of the markers into the cir-
culation. Therefore, in the emergency department, risk in-
dices are more favorable for the prognosis in comparison 
with ECG findings and troponin concentration (11,28). In 
recent studies, acute branch block (29,30), post interven-
tional TIMI flow through the IRA (31,32), and left ventricle 
ejection fraction (31,33) were found prognostically impor-
tant for long-term outcome. Furthermore, an anterior wall 
MI was associated with a significantly higher risk of mor-
tality than an inferior wall MI. Renal insufficiency and age 
were emphasized as good MACE predictors (32-36). All 
these variables are included in the RISK-PCI score and this 
fact probably increases its predictive accuracy. Leukocyte 
count on admission makes the crucial difference between 
RISK-PCI and other two scoring systems, because its in-
creased value positively correlates with lower subepicar-
dial flow, frequent left chamber remodeling, congestive 











(95% CI for RR) P
RR
(95% CI for RR) P
RR
(95% CI for RR) P
RR
(95% CI for RR)
RISK PCI 0.002 2.180 (1.339-3.548) <0.001 2.003 (1.392-2.882) <0.001 2.791 (1.790-4.353) <0.001 2.422 (1.429-3.519)
GRACE on admission 0.001 1.045 (1.018-1.072)  0.395 1.008 (0.989-1.028) <0.001 1.029 (1.013-1.045) / /
GRACE on discharge 0.047 1.029 (1.000-1.058)  0.538 1.006 (0.986-1.027)  0.058 1.016 (0.999-1.033) / /
TIMI 0.100 1.420 (0.935-2.156)  0.987 1.003 (0.728-1.382)  0.243 1.160 (0.904-1.490) / /
*Abbreviations: TVR – target-vessel revascularization; MACE – major adverse cardiac events; RISK-PCI – the score predicting 30-day major adverse 
cardiovascular events after primary percutaneous coronary intervention; GRACE - Global Registry for Acute Coronary Events; TIMI – thrombolysis in 
myocardial infarction; CI – confidence intervals; RR – relative risk.
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heart failure, and fatal outcome (37). Angiographic pa-
rameters are omitted from the GRACE score on admission 
and the TIMI score, while GRACE score on discharge takes 
into consideration only two similar variables, prior MI and 
eventual PCI performance (8). In the RISK-PCI score, angio-
graphic assessment of the diameter of the infraction-relat-
ed coronary artery and its TIMI flow are considered as the 
factor for the overall evaluation of the patient’s condition 
and subsequent selection on the basis of the seriousness 
of the symptoms. We found the RISK-PCI score to be an 
independent predictor of death, urgent revascularization, 
and composite MACE, and the GRACE score on admission 
to be an independent predictor of the fatal outcome after 
the 30-day follow-up period.
The main limitation of our study lies in its retrospective 
and single-center-based design. In consistency with the 
widely accepted risk models for primary PCI, patients with 
cardiogenic shock at presentation were excluded from 
the trial. These patients by definition fall into the highest-
risk category and their treatment differs from the overall 
primary PCI population in terms of the time window for 
revascularization (no time limit) and the extent of revascu-
larization (complete revascularization recommended). We 
performed only femoral approach in the aforementioned 
period. Therefore, our results do not refer to the radial ap-
proach.
Given a relatively small number of patients in our study, the 
results of the study should be considered as hypothesis-
generating and further verified in a larger trial in future.
In conclusion, RISK-PCI showed a reasonably fair discrimi-
native ability for the 30-day MACE in ACS patients. In com-
parison with the GRACE and TIMI scores, the RISK-PCI score 
showed a non-inferior ability to predict 30-day MACE and 
death and was the only index that could predict recurrent 
ischemia requiring TVR. Further research in larger patient 
cohorts is needed for the clinical validation of RISK-PCI 
score in patients with UA/NSTEMI.
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